International Stem Cell Corporation
is a biotechnology company utilizing a proprietary new stem cell technology
known as parthenogenesis to significantly advance the field of regenerative
medicine. The company’s innovative technology uses unfertilized human eggs to
create human pluripotent stem cells (hpSC) that can be immune-matched to
millions of people around the globe. These stem cells are unique in that they
provide the best characteristics of each of the remaining classes of cells
without the need for the creation or destruction of a viable embryo.
The company’s business strategy
features three unique channels for revenue generation within the biotechnology
industry – including its core stem cell technology and related intellectual
property, which encompasses 220 patents, applications and licenses associated
with the development and manufacture of pluripotent cells, as well as its
therapeutic research projects and promising development pipeline.
Lifeline Skin Care, the company’s
wholly-owned subsidiary, is an industry leader in effective anti-aging stem
cell skin care. Since being established in 2010, Lifeline has served as a
growing source of vital financial support to fund ISCO’s ongoing medical
research. In 2014, Lifeline accounted for more than $7 million in total
revenue, which was primarily allocated to the advancement of the company’s
promising development pipeline.
UniStemCell is the life science
industry’s first collection of non-embryonic histocompatible human stem cells
available for research and commercial use. This cell bank gives the company a
nearly inexhaustible source of stem cells that can be used to generate revenue
in the medium term. As the company’s hpSC lines gain additional validation,
they are expected to provide the company with royalty from sales of each
successful hpSC-derived cellular therapeutic in the future.
In addition to the sale of its stem
cells, ISCO is making noteworthy progress toward the continued advancement of
its development pipeline. The company is currently engaged in pre-clinical
development addressing a host of unmet medical needs. Parkinson’s disease,
which affects an estimated one million people in the United States, represents
ISCO’s leading development indication, with phase I/II clinical trials expected
to begin in the coming months. Following the completion of initial studies, the
company will seek out a suitable partner to assist with late-stage clinical
development.
With its groundbreaking stem cell
technology, ISCO is developing a significant presence within the expansive
field of regenerative medicine. By successfully mitigating many of the limiting
factors commonly associated with stem cell research – including auto-immune
rejection and ethical debate surrounding the use of embryonic cells – the company
is leveraging the marketability of its technology as a catalyst for continued
growth.
Research indicates that the global
regenerative medicine market is expected to grow at a CAGR of 12.2 percent
through 2017, climbing to an estimated $24.7 billion by the end of the period.
ISCO will look to capitalize on this market performance under the guidance of
an executive management team with decades of experience in a collection of
related scientific sectors.
For more information, visit
www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
